Compare · CBUS vs CLXT
CBUS vs CLXT
Side-by-side comparison of Cibus Inc. (CBUS) and Calyxt Inc. (CLXT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBUS and CLXT operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- CBUS is the larger of the two at $128.4M, about 2.1x CLXT ($62.0M).
- CBUS has hit the wire 3 times in the past 4 weeks while CLXT has been quiet.
- CBUS has more recent analyst coverage (4 ratings vs 2 for CLXT).
- Company
- Cibus Inc.
- Calyxt Inc.
- Price
- -
- -
- Market cap
- $128.4M
- $62.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2017
- News (4w)
- 3
- 0
- Recent ratings
- 4
- 2
Calyxt Inc.
Calyxt, Inc., a technology company, focuses on delivering plant-based solutions in the United States. It engages in the development of improved digestibility alfalfa; high fiber wheat; high oleic low linolenic soybeans; winter oats; hemp; fat soybeans; and cold storable potatoes. As of March 4, 2021, the company had nine projects at Phase I stage or later in development across alfalfa, hemp, oats, soybeans, and wheat. Calyxt, Inc. has a research collaboration with NRGene, which includes the adoption of NRGene's cloud-based genomics platform to support various research projects; and a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and various geographies outside the United States. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.
Latest CBUS
- SEC Form 10-Q filed by Cibus Inc.
- Cibus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cibus Reports Second Quarter Financial Results and Provides Business Update
- Cibus to Report Second Quarter 2026 Financial Results on August 13, 2026 After the Market Close and Host Conference Call
- SEC Form S-8 filed by Cibus Inc.
- SEC Form S-8 filed by Cibus Inc.
- Europe Recognizes Nature-Based Plant Improvement, Opening a New Pathway for Cibus
- CEO Wichner Craig was granted 894,309 shares (SEC Form 4)
- Cibus Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation
Latest CLXT
- Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer
- SEC Form SC 13G/A filed by Calyxt Inc. (Amendment)
- Calyxt Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Riggs Rory B converted options into 1,500,000 shares and acquired 1,505,967 units of Class B Common Stock, increasing direct ownership by 128% to 3,103,788 units (SEC Form 4)
- Calyxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Calyxt Inc.
- Calyxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Riggs Rory B disposed of 39,476 shares and bought $5,470,992 worth of shares (517,107 units at $10.58), increasing direct ownership by 47% to 1,622,495 units (SEC Form 4)
- Calyxt Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Calyxt Inc.